Contract Research Firm CMIC Joins Pharma Market With Orphan Drug, With More On The Way
This article was originally published in PharmAsia News
Novartis and Novo Nordisk receive first global approvals for compounds in Japan in recent slate of approvals, along with a wave of government-subsidized orphan drugs.
You may also be interested in...
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.